EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome

Xavier Jeunemaitre iD, Elie Mousseaux iD, Michael Frank iD, Salma Adham iD, Francesca Pitocco iD, Clarisse Billon, Molka Ben Yakhlef, Mohamed El Hachmi iD, Alessandra Bura-Rivière iD, François-Xavier Lapébie iD, Claire Le Hello iD, Damien Laneelle iD und 14 weitere

Circulation · 11.03.2025 · 151 (10) · 686-695

DOI: 10.1161/circulationaha.124.072849 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 11.03.2025. Verfasst von Xavier Jeunemaitre und 25 weiteren Autor:innen. Beteiligte Einrichtung: PARCC (X.J., E.M., P.B., T.M., G.C.), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité, France. Hauptthemen laut MEDLINE: Ehlers-Danlos Syndrome, Celiprolol, Biphenyl Compounds, Angiotensin II Type 1 Receptor Blockers. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular Ehlers-Danlos syndrome is a rare genetic disorder characterized by defective type III collagen and a high risk of arterial morbidity and mortality. Several cardiovascular drugs are used for treatment, including celiprolol, but no controlled trial in this condition has been conducted to date. We hypothesized the benefit of the addition of an angiotensin II receptor blocker. METHODS: A multicenter, randomized, placebo-controlled trial was conducted to assess the efficacy and safety of the angiotensin II receptor blocker irbesartan in adults with vascular Ehlers-Danlos syndrome on stable background celiprolol therapy. Patients were randomized 1:1 to receive irbesartan (150 mg/day titrated to 300 mg/day) or placebo for 2 years. The composite primary outcome was defined as any vascular Ehlers-Danlos syndrome–related fatal or nonfatal arterial event or any new or worsening arterial lesions detected by systematic head-to-pelvis computed tomography angiography or peripheral arterial duplex ultrasound at different time points, using a time-to-first-event analysis. RESULTS: Twenty-nine participants (62% female; 40.3±11.3 years of age) were randomized to irbesartan, and 28 (64% female; 40.7±11.0 years of age) were randomized to placebo. The composite primary outcome occurred in 8 of 29 patients (27.6%) receiving irbesartan versus 15 of 28 patients (53.6%) receiving placebo (hazard ratio, 0.42 [95% CI, 0.17, 0.99]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ehlers-Danlos SyndromeCeliprololBiphenyl CompoundsAngiotensin II Type 1 Receptor BlockersTetrazolesHumansIrbesartanFemaleMaleAdultMiddle AgedTreatment OutcomeDouble-Blind MethodEhlers-Danlos Syndrome, Type IV

Stichwörter der Autor:innen

Ehlers-Danlos syndrome, type IVangiotensin receptor antagonistsceliprololcollagencomputed tomography angiography

Substanzen

IrbesartanCeliprololBiphenyl CompoundsAngiotensin II Type 1 Receptor BlockersTetrazoles

Autor:innen und Institutionen

  • PARCC (X.J., E.M., P.B., T.M., G.C.), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité, France.
  • AP-HP, Hôpital Européen Georges-Pompidou, Service de Médecine Génomique des Maladies Rares et DMU BioPhyGen (X.J., C. Billon, M.B.Y.), AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
  • AP-HP, Hôpital Européen Georges-Pompidou, Service de Radiologie Vasculaire (E.M., F.P.), AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
  • AP-HP, Hôpital Européen Georges-Pompidou, Service de Médecine Vasculaire et Centre de Référence des Maladies Artérielles Rares (M.F., S.A., M.E.H., N.D., T.M.), AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
  • Service de Médecine Vasculaire, Hôpital Saint-Eloi, CHU Montpellier, France (S.A.).
  • Dipartimento Medicina Molecolare, University La Sapienza, Italy (M.E.H.).

ORCID-Profile: Xavier Jeunemaitre, Elie Mousseaux, Michael Frank, Salma Adham, Francesca Pitocco, Mohamed El Hachmi, Alessandra Bura-Rivière, François-Xavier Lapébie, Claire Le Hello, Damien Laneelle, Christophe Seinturier, Klaus Dieterich, Sophie Dupuis-Girod, Stéphane Zuily, Laurence Bal-Theoleyre, Estelle Lu, Pierre Boutouyrie, Tristan Mirault, Gilles Chatellier, Michel Azizi

Zitieren

APA

Jeunemaitre, X., Mousseaux, E., Frank, M., Adham, S., Pitocco, F., Billon, C., Ben Yakhlef, M., El Hachmi, M., Bura-Rivière, A., Lapébie, F. X., Le Hello, C., Laneelle, D., Seinturier, C., Dieterich, K., Lambert, M., Dupuis-Girod, S., Zuily, S., Bal-Theoleyre, L., Boulon, C., …, & Azizi, M. (2025). Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome. Circulation, 151(10), 686-695. https://doi.org/10.1161/circulationaha.124.072849

Vancouver

Jeunemaitre X, Mousseaux E, Frank M, Adham S, Pitocco F, Billon C, et al. Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome. Circulation. 2025;151(10):686-695. doi:10.1161/circulationaha.124.072849

BibTeX
@article{Jeunemaitre2025,
  author = {Jeunemaitre, Xavier and Mousseaux, Elie and Frank, Michael and Adham, Salma and Pitocco, Francesca and Billon, Clarisse and Ben Yakhlef, Molka and El Hachmi, Mohamed and Bura-Rivière, Alessandra and Lapébie, François-Xavier and Le Hello, Claire and Laneelle, Damien and Seinturier, Christophe and Dieterich, Klaus and Lambert, Marc and Dupuis-Girod, Sophie and Zuily, Stéphane and Bal-Theoleyre, Laurence and Boulon, Carine and Henneton, Pierrick and Lu, Estelle and Denarié, Nicolas and Boutouyrie, Pierre and Mirault, Tristan and Chatellier, Gilles and Azizi, Michel},
  title = {Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {10},
  pages = {686--695},
  doi = {10.1161/circulationaha.124.072849}
}
Kostenlos starten →